PTC Therapeutics, Inc.
PTCT
$75.25
-$0.92-1.21%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.78B | 1.76B | 1.77B | 806.78M | 900.66M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.78B | 1.76B | 1.77B | 806.78M | 900.66M |
| Cost of Revenue | 503.24M | 559.56M | 582.84M | 591.88M | 601.30M |
| Gross Profit | 1.28B | 1.21B | 1.19B | 214.90M | 299.37M |
| SG&A Expenses | 334.95M | 324.36M | 308.60M | 300.91M | 292.52M |
| Depreciation & Amortization | 18.70M | 14.20M | 13.01M | 60.74M | 134.61M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 856.89M | 898.12M | 904.45M | 953.53M | 1.03B |
| Operating Income | 922.26M | 866.81M | 868.31M | -146.75M | -127.76M |
| Income Before Tax | 741.00M | 666.09M | 651.41M | -363.12M | -425.47M |
| Income Tax Expenses | -10.72M | 36.91M | 56.56M | 176.00K | 27.73M |
| Earnings from Continuing Operations | 751.72 | 629.17 | 594.84 | -363.30 | -453.20 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 751.72M | 629.17M | 594.84M | -363.30M | -453.20M |
| EBIT | 922.26M | 866.81M | 868.31M | -146.75M | -127.76M |
| EBITDA | 954.94M | 894.86M | 895.80M | -71.08M | 21.85M |
| EPS Basic | 9.61 | 8.02 | 7.56 | -4.73 | -5.94 |
| Normalized Basic EPS | 6.99 | 6.43 | 6.38 | -1.77 | -2.32 |
| EPS Diluted | 8.55 | 6.97 | 6.50 | -4.74 | -5.95 |
| Normalized Diluted EPS | 6.30 | 5.72 | 5.67 | -1.77 | -2.32 |
| Average Basic Shares Outstanding | 311.94M | 310.39M | 308.97M | 307.35M | 305.64M |
| Average Diluted Shares Outstanding | 328.85M | 318.66M | 317.24M | 307.35M | 305.64M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |